{"id":"NCT00421954","sponsor":"New York State Psychiatric Institute","briefTitle":"Open-label Ziprasidone Study for Psychosis Treatment in Adolescents","officialTitle":"Open-label Feasibility Study for the Treatment of Psychotic Adolescents With Ziprasidone in the Inpatient and Day Hospital Settings","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-05","primaryCompletion":"2008-05","completion":"2009-05","firstPosted":"2007-01-15","resultsPosted":"2017-01-13","lastUpdate":"2017-01-13"},"enrollment":8,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Schizophreniform Disorder","Schizoaffective Disorder","Psychosis","Depressive Disorder, Major","Bipolar Disorder"],"interventions":[{"type":"DRUG","name":"Ziprasidone","otherNames":[]}],"arms":[{"label":"Ziprasidone","type":"EXPERIMENTAL"}],"summary":"This open-label study will assess the medication Geodon® (Ziprasidone) in pediatric patients, aged 13-17, diagnosed with psychotic disorder. Eligible adolescents will receive Geodon® for 7 weeks and stay at the NYSPI Children's Day Unit (CDU) during the day. If clinically appropriate, they may also stay at the New York State Psychiatric Institute (NYSPI) Schizophrenia Research Unit (SRU) inpatient facility.","primaryOutcome":{"measure":"Weight Gain and Other Side Effects","timeFrame":"couple of months","effectByArm":[],"pValues":[]},"eligibility":{"minAge":"13 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":0},"commonTop":[]}}